Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Hyunwook Cho"'
Autor:
Daseul Im, Joonhong Jun, Jihyun Baek, Haejin Kim, Dahyun Kang, Hyunah Bae, Hyunwook Cho, Jung-Mi Hah
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 472-486 (2022)
Fms-like tyrosine kinase 3 (FLT3) has been verified as a therapeutic target for acute myeloid leukaemia (AML). In this study, we report a series of 2-(1H-indazol-6-yl)-1H-benzo[d]imidazol-5-yl benzamide and phenyl urea derivatives as potent FLT3 inhi
Externí odkaz:
https://doaj.org/article/3b5f7ce66d344764bc9eb1d10213a431
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 35, Iss 1, Pp 372-376 (2020)
3-alkyl-5-aryl-1-pyrimidyl-1H-pyrazole derivatives were designed and synthesised as selective inhibitors of JNK3, a target for the treatment of neurodegenerative diseases. Following previous studies, we have designed JNK3 inhibitors to reduce the mol
Externí odkaz:
https://doaj.org/article/8cf4d412b5ed44ec9b5cedf3e9def8dd
Autor:
Hyunwook Cho, Jung-Mi Hah
Publikováno v:
Biomedicines, Vol 9, Iss 10, p 1431 (2021)
c-Jun N-terminal kinase (JNK) plays an important role in cell death caused by various stimuli. Because the isoform JNK3 is mainly expressed in the brain, it is believed to play a pivotal role in various neurodegenerative diseases, including Alzheimer
Externí odkaz:
https://doaj.org/article/7066b2a32df9438383742b52a2ccf542
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 20, p 11084 (2021)
As members of the MAPK family, c-Jun-N-terminal kinases (JNKs) regulate the biological processes of apoptosis. In particular, the isoform JNK3 is expressed explicitly in the brain at high levels and is involved in the pathogenesis of neurodegenerativ
Externí odkaz:
https://doaj.org/article/8a70d9e28a464869a9270dfa8575aed4
Autor:
Youri Oh, Hoyong Jung, Hyejin Kim, Jihyun Baek, Joonhong Jun, Hyunwook Cho, Daseul Im, Jung-Mi Hah
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 8, p 3865 (2021)
Polo-like kinase 1 (PLK1) plays an important role in cell cycle progression and proliferation in cancer cells. PLK1 also contributes to anticancer drug resistance and is a valuable target in anticancer therapeutics. To identify additional effective P
Externí odkaz:
https://doaj.org/article/2d04976252ae46aca27d2dc5b7556273
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 5, p 1698 (2020)
We designed and synthesized 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo [3,4-d] imidazole-5(1H)-carboxamide derivatives as selective inhibitors of c-Jun-N-terminal Kinase 3 (JNK3), a target for the treatment of neurodegenerative diseases. Based on the c
Externí odkaz:
https://doaj.org/article/d9148fd904a1485d906280224d467280
Publikováno v:
Journal of Clinical Medicine, Vol 8, Iss 11, p 1996 (2019)
Spinal stenosis is a common condition in elderly individuals. Many patients are unresponsive to the conventional treatment. If the transforaminal epidural block does not exert a sufficient treatment effect, percutaneous transforaminal epidural adhesi
Externí odkaz:
https://doaj.org/article/b2eb9f386bc84375a158cbf0cb227ee8
Publikováno v:
Korean Journal of Anesthesiology, Vol 66, Iss 2, Pp 164-168 (2014)
Antiphospholipid syndrome (APS) is a rare disease in which patients display prolonged coagulation test results in vitro, but usually develop thrombotic symptoms in vivo. Patients with APS are at increased risk of valvular heart disease or coronary va
Externí odkaz:
https://doaj.org/article/3f9c0d2d70124fe3b09d2a735bd48f73
Autor:
Joonhong Jun, Hyungwoo Moon, Songyi Yang, Junghun Lee, Jihyun Baek, Hyejin Kim, Hyunwook Cho, Kyungrim Hwang, Soyeon Ahn, Yuro Kim, Gibeom Kim, HyunTae Kim, Hoseok Kwon, Jung-Mi Hah
Publikováno v:
Journal of Medicinal Chemistry. 66:6372-6390
Publikováno v:
European journal of medicinal chemistry. 245(Pt 1)
JNK3 is a key factor driving the pathophysiology of neuronal apoptosis. Since demonstrating the therapeutic potential of JNK3 inhibitors in Alzheimer's disease, we aimed to broaden their chemical diversity for drug development. In continuation with o